In examining recent analyst actions, we gain insights into how financial experts perceive Eli Lilly. The following summary outlines key analysts, their recent evaluations, and adjustments to ...

Now, this won't come as too much of a surprise to Eli Lilly and its peers. A few weeks ago, the company's CEO, David Ricks, ...

Rather counterintuitively, following some promising news about a pipeline drug, one analyst tracking Eli Lilly (NYSE: LLY) stock cut his price target on the pharmaceutical giant. Even though that ...

LLY has delivered impressive returns of 15% year-to-date (as of April 30), outperforming the S&P 500’s 5% decline during the ...

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

Bernstein Senior Analyst, US Biopharmaceuticals Courtney ... industry and painted the order as a blow against drugmakers. Eli Lilly (NYSE:LLY) recently announced the impressive results of its ...

Eli Lilly (NYSE:LLY) harnessed significant operational performance during the latest quarter, reporting robust sales and net ...

The Indianapolis-based drugmaker also reaffirmed its 2025 revenue guidance but noted that the calculation was based on ...

Click here for access. * An analyst from Morgan Stanley persists with their Overweight rating on Eli Lilly, maintaining a target price of $1124. * In a positive move, an analyst from Goldman Sachs ...

While arch rival Eli Lilly and Company ... a step function change for Lilly’s market leadership over NVO and its peers. Lilly management provided insights into the advantages of why the ...

Rather counterintuitively, following some promising news about a pipeline drug, one analyst tracking Eli Lilly (NYSE: LLY) stock cut his price target on the pharmaceutical giant. Even though that ...